News & Updates
Filter by Specialty:
Hydrochlorothiazide use poses risk of cutaneous squamous cell carcinoma among diabetics
Type 2 diabetes (T2D) patients exposed to hydrochlorothiazide for more than 2 years appear to be at higher risk of cutaneous squamous cell carcinoma (cSCC), as reported in a recent study.
Hydrochlorothiazide use poses risk of cutaneous squamous cell carcinoma among diabetics
09 Nov 2021
Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer
Fatty acid synthase (FASN) is commonly expressed in operable triple-negative breast cancer (TNBC) and is associated with a poor prognosis, but omeprazole can hamper FASN activity, which may potentially boost the efficacy of neoadjuvant chemotherapy, according to the results of a phase II study.
Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer
08 Nov 2021
Quadruple therapy with empagliflozin/dapagliflozin affords long-term glycaemic control
A four-drug combination that includes either empagliflozin or dapagliflozin helps keep glucose in check through 3 years for patients with type 2 diabetes (T2D), in addition to its positive effect on weight and tolerable safety profile, as shown in an open-label randomized controlled study.
